Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Vigil Neuroscience Inc (VIGL)

Vigil Neuroscience Inc (VIGL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 130,404
  • Shares Outstanding, K 40,879
  • Annual Sales, $ 0 K
  • Annual Income, $ -82,640 K
  • EBIT $ -88 M
  • EBITDA $ -90 M
  • 60-Month Beta 1.92
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.34

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.57
  • Number of Estimates 5
  • High Estimate -0.47
  • Low Estimate -0.69
  • Prior Year -0.57
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.89 +10.38%
on 11/18/24
4.06 -21.43%
on 11/06/24
-0.50 (-13.55%)
since 10/22/24
3-Month
2.89 +10.38%
on 11/18/24
4.12 -22.57%
on 10/17/24
-0.24 (-7.00%)
since 08/22/24
52-Week
2.47 +29.15%
on 06/04/24
6.06 -47.36%
on 06/07/24
+0.22 (+7.41%)
since 11/22/23

Most Recent Stories

More News
Vigil Neuroscience to Present at Upcoming Investor Conferences

VIGL : 3.19 (+6.33%)
Vigil Neuroscience Reports Third Quarter 2024 Financial Results and Provides Business Update

VIGL : 3.19 (+6.33%)
Vigil Neuroscience to Present at Guggenheim Healthcare Innovation Conference

VIGL : 3.19 (+6.33%)
Gilead Boosts Biotech Footprint With Stakes In AlloVir And Arcus

Regulatory filings show Gilead Sciences' purchase of shares in AlloVir and Arcus. Strategic investments in the biotech sector are fairly common to boost growth.

GILD : 90.19 (+0.48%)
AMGN : 294.53 (+1.60%)
BMY : 58.87 (+1.10%)
NVS : 104.28 (+0.41%)
BGNE : 190.51 (-2.08%)
JSPR : 22.05 (+0.96%)
VIGL : 3.19 (+6.33%)
ALVR : 0.5499 (-3.53%)
RCUS : 14.70 (+2.94%)
FLACU : 9.50 (+2.48%)
Vigil Neuroscience Reports Second Quarter 2022 Financial Results and Provides Business Update

– Initiated a Phase 1 trial of VGL101 in healthy volunteers in Australia – – Received U.S. FDA orphan drug designation for VGL101 for the treatment of...

VIGL : 3.19 (+6.33%)
Vigil Neuroscience to Present at 2022 Wedbush PacGrow Healthcare Virtual Conference

CAMBRIDGE, Mass., Aug. 02, 2022 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to...

VIGL : 3.19 (+6.33%)
Vigil Neuroscience Presents Preclinical Data on VGL101 for Adult-Onset Leukoencephalopathy with Axonal Spheroids and Pigmented Glia (ALSP) and Clinical Phenotype of ALSP at Alzheimer's Association International Conference 2022

CAMBRIDGE, Mass., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to...

VIGL : 3.19 (+6.33%)
Vigil Neuroscience Expands VGL101 Phase 1 Trial to Australia

- Received approval from the Human Research Ethics Committee in Australia to initiate a Phase 1 trial of VGL101 in healthy volunteers at doses above 20...

VIGL : 3.19 (+6.33%)
Vigil Neuroscience Reports First Quarter 2022 Financial Results and Provides Business Highlights

- Presented key findings enhancing clinical understanding of ALSP at the 2022 American Academy of Neurology Annual Meeting - - Expanded leadership team...

VIGL : 3.19 (+6.33%)
Vigil Neuroscience Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Highlights

- Completed successful initial public offering, raising $98 million in gross proceeds - - Initiated VGL101 Phase 1 trial; Phase 2 trial in ALSP patients...

VIGL : 3.19 (+6.33%)

Business Summary

Vigil Neuroscience Inc. is a microglia-focused therapeutics company. It focused on developing treatments for both rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Vigil Neuroscience Inc. is based in CAMBRIDGE, Mass.

See More

Key Turning Points

3rd Resistance Point 3.57
2nd Resistance Point 3.41
1st Resistance Point 3.30
Last Price 3.19
1st Support Level 3.03
2nd Support Level 2.87
3rd Support Level 2.76

See More

52-Week High 6.06
Fibonacci 61.8% 4.69
Fibonacci 50% 4.26
Fibonacci 38.2% 3.84
Last Price 3.19
52-Week Low 2.47

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar